Literature DB >> 10748219

Kinetic investigation of the specificity of porcine brain thyrotropin-releasing hormone-degrading ectoenzyme for thyrotropin-releasing hormone-like peptides.

J A Kelly1, G R Slator, K F Tipton, C H Williams, K Bauer.   

Abstract

Evidence indicates that neuronally released thyrotropin-releasing hormone (TRH) is selectively inactivated by TRH-degrading ectoenzyme (TRH-DE) (EC ). TRH-DE inhibitors may be used to enhance the therapeutic actions of TRH and to investigate the functions of TRH and TRH-DE in the central nervous system. Although TRH-DE appears to exhibit a high degree of specificity toward TRH, systematic specificity studies, which would facilitate inhibitor design, have not been previously conducted for this enzyme. In this paper we present the first description of TRH-DE specificity across a directed peptide library in which the histidyl (P(1)') residue of TRH was replaced by a series of amino acids. Peptides were synthesized using standard solid phase chemistry. Kinetic parameters were measured either by continuous or discontinuous fluorometric assays or by quantitative high pressure liquid chromatography. The P(1)' residue was found to influence significantly both the ability of the peptides to bind to TRH-DE, as measured by their K(i) values, and the ability of TRH-DE to catalyze their hydrolysis. Moderately bulky, uncharged P(1)' residues were found to bind preferentially to TRH-DE. Results from this screen provide valuable information for the development of TRH-DE inhibitors and have led to the identification of two potent, reversible TRH-DE inhibitors, l-pyroglutamyl-l-asparaginyl-l-prolineamide (K(i) = 17.5 micrometer) and Glp-Asn-Pro-7-amido-4-methyl coumarin (K(i) = 0.97 micrometer).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10748219     DOI: 10.1074/jbc.M910386199

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Structure-activity studies with high-affinity inhibitors of pyroglutamyl-peptidase II.

Authors:  Julie A Kelly; Gaia A Scalabrino; Gillian R Slator; Aoife A Cullen; John F Gilmer; David G Lloyd; Geoffrey W Bennett; Karl Bauer; Keith F Tipton; Carvell H Williams
Journal:  Biochem J       Date:  2005-07-15       Impact factor: 3.857

2.  [Glu2]TRH dose-dependently attenuates TRH-evoked analeptic effect in mice.

Authors:  Vien Nguyen; Alevtina D Zharikova; Katalin Prokai-Tatrai; Laszlo Prokai
Journal:  Brain Res Bull       Date:  2010-02-24       Impact factor: 4.077

3.  Pyroglutamyl peptidase type I from Trypanosoma brucei: a new virulence factor from African trypanosomes that de-blocks regulatory peptides in the plasma of infected hosts.

Authors:  Rory E Morty; Patrick Bulau; Roger Pellé; Sherwin Wilk; Koji Abe
Journal:  Biochem J       Date:  2006-03-15       Impact factor: 3.857

4.  Discovery of a low affinity thyrotropin-releasing hormone (TRH)-like peptide that exhibits potent inhibition of scopolamine-induced memory impairment in mice.

Authors:  Chhuttan L Meena; Shubdha Ingole; Satyendra Rajpoot; Avinash Thakur; Prajwal P Nandeker; Abhay T Sangamwar; Shyam S Sharma; Rahul Jain
Journal:  RSC Adv       Date:  2015-06-23       Impact factor: 3.361

5.  Design and exploratory neuropharmacological evaluation of novel thyrotropin-releasing hormone analogs and their brain-targeting bioprecursor prodrugs.

Authors:  Katalin Prokai-Tatrai; Vien Nguyen; Szabolcs Szarka; Krisztina Konya; Laszlo Prokai
Journal:  Pharmaceutics       Date:  2013       Impact factor: 6.321

Review 6.  The Thyrotropin-Releasing Hormone-Degrading Ectoenzyme, a Therapeutic Target?

Authors:  Jean-Louis Charli; Adair Rodríguez-Rodríguez; Karina Hernández-Ortega; Antonieta Cote-Vélez; Rosa María Uribe; Lorraine Jaimes-Hoy; Patricia Joseph-Bravo
Journal:  Front Pharmacol       Date:  2020-05-08       Impact factor: 5.810

Review 7.  Prodrugs of thyrotropin-releasing hormone and related peptides as central nervous system agents.

Authors:  Katalin Prokai-Tatrai; Laszlo Prokai
Journal:  Molecules       Date:  2009-02-06       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.